Omeros (OMER) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

OMER Stock Forecast

Omeros stock forecast is as follows: an average price target of $2.00 (represents a -66.83% downside from OMER’s last price of $6.03) and a rating consensus of 'Hold', based on 1 wall street analysts offering a 1-year stock forecast.

OMER Price Target

The average price target for Omeros (OMER) is $2.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $2.00 to $2.00. This represents a potential -66.83% downside from OMER's last price of $6.03.

OMER Analyst Ratings

Hold

According to 1 Wall Street analysts, Omeros's rating consensus is 'Hold'. The analyst rating breakdown for OMER stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 1 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Omeros Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Dec 08, 2022	-	UBS	$2.00	$2.02	-1.23%	-66.83%

Row per page

Go to

The latest Omeros stock forecast, released on Dec 08, 2022 by UBS company, set a price target of $2.00, which represents a -1.23% decrease from the stock price at the time of the forecast ($2.02), and a -66.83% decrease from OMER last price ($6.03).

Omeros Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$6.03	$6.03	$6.03
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of Omeros stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Omeros's last price of $6.03. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Dec 08, 2022	UBS	-	Neutral	Downgrade

Row per page

Go to

Omeros's last stock rating was published by UBS on Dec 08, 2022. The company Downgrade its OMER rating from "null" to "Neutral".

Omeros Financial Forecast

Omeros Revenue Forecast

	Dec 24	Sep 24	Jun 24	Sep 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13	Mar 12	Mar 11	Mar 10	Sep 09
Revenue	-	-	-	-	-	$-79.89M	$30.00M	$28.82M	$21.06M	$10.63M	$26.11M	$13.53M	$23.54M	$33.42M	$29.86M	$26.75M	$21.78M	$1.59M	$12.26M	$7.42M	$388.00K	$100.00K	$1.09M	$1.50M	$1.24M	$378.00K	$442.00K
Avg Forecast	-	-	-	$2.79M	$10.21M	$66.92M	$27.96M	$24.27M	$20.53M	$14.91M	$20.82M	$17.10M	$30.43M	$31.74M	$28.29M	$24.52M	$23.18M	$1.59M	$12.98M	$5.91M	$479.29K	$83.33K	$1.07M	$1.54M	$1.61M	$365.81K	$489.78K
High Forecast	-	-	-	$2.79M	$10.21M	$66.92M	$27.96M	$24.27M	$20.53M	$14.91M	$20.82M	$17.10M	$30.43M	$31.74M	$28.29M	$24.52M	$23.18M	$1.91M	$15.57M	$7.09M	$575.15K	$100.00K	$1.28M	$1.85M	$1.93M	$438.97K	$587.74K
Low Forecast	-	-	-	$2.79M	$10.21M	$66.92M	$27.96M	$24.27M	$20.53M	$14.91M	$20.82M	$17.10M	$30.43M	$31.74M	$28.29M	$24.52M	$23.18M	$1.27M	$10.38M	$4.73M	$383.43K	$66.67K	$854.10K	$1.23M	$1.29M	$292.64K	$391.83K
# Analysts	-	-	-	16	10	9	9	13	9	9	15	9	9	16	8	10	16	18	19	8	8	13	14	16	11	11	16
Surprise %	-	-	-	-	-	-1.19%	1.07%	1.19%	1.03%	0.71%	1.25%	0.79%	0.77%	1.05%	1.06%	1.09%	0.94%	1.00%	0.94%	1.26%	0.81%	1.20%	1.03%	0.97%	0.77%	1.03%	0.90%

Omeros's average Quarter revenue forecast for Mar 22 based on 10 analysts is $10.21M, with a low forecast of $10.21M, and a high forecast of $10.21M. OMER's average Quarter revenue forecast represents a -112.78% decrease compared to the company's last Quarter revenue of $-79.89M (Dec 21).

Omeros EBITDA Forecast

	Dec 24	Sep 24	Jun 24	Sep 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13	Mar 12	Mar 11	Mar 10	Sep 09
# Analysts	-	-	-	16	10	9	9	13	9	9	15	9	9	16	8	10	16	18	19	8	8	13	14	16	11	11	16
EBITDA	-	-	-	$-49.54M	$-34.27M	$285.89M	$-17.48M	$-23.33M	$-29.80M	$-33.04M	$-39.03M	$-26.90M	$-22.73M	$-22.89M	$-10.31M	$-8.47M	$-18.37M	$-27.01M	$-12.31M	$-19.11M	$-17.66M	$-15.89M	$-9.84M	$-8.31M	$-6.08M	$-6.08M	$-3.27M
Avg Forecast	-	-	-	$808.22K	$-42.96M	$19.37M	$8.09M	$7.02M	$-29.80M	$4.32M	$6.03M	$4.95M	$-11.03M	$9.19M	$8.19M	$7.10M	$-19.07M	$-27.01M	$-12.99M	$-14.22M	$-21.02M	$-12.71M	$-9.58M	$-8.54M	$-7.48M	$-5.88M	$-3.63M
High Forecast	-	-	-	$808.22K	$-34.37M	$19.37M	$8.09M	$7.02M	$-23.84M	$4.32M	$6.03M	$4.95M	$-8.82M	$9.19M	$8.19M	$7.10M	$-15.26M	$-21.60M	$-10.40M	$-11.38M	$-16.82M	$-10.17M	$-7.67M	$-6.83M	$-5.99M	$-4.71M	$-2.90M
Low Forecast	-	-	-	$808.22K	$-51.56M	$19.37M	$8.09M	$7.02M	$-35.76M	$4.32M	$6.03M	$4.95M	$-13.23M	$9.19M	$8.19M	$7.10M	$-22.89M	$-32.41M	$-15.59M	$-17.07M	$-25.22M	$-15.25M	$-11.50M	$-10.25M	$-8.98M	$-7.06M	$-4.35M
Surprise %	-	-	-	-61.30%	0.80%	14.76%	-2.16%	-3.32%	1.00%	-7.66%	-6.48%	-5.44%	2.06%	-2.49%	-1.26%	-1.19%	0.96%	1.00%	0.95%	1.34%	0.84%	1.25%	1.03%	0.97%	0.81%	1.03%	0.90%

10 analysts predict OMER's average Quarter EBITDA for Mar 22 to be $-42.96M, with a high of $-34.37M and a low of $-51.56M. This is -115.03% lower than Omeros's previous annual EBITDA (Dec 21) of $285.89M.

Omeros Net Income Forecast

	Dec 24	Sep 24	Jun 24	Sep 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13	Mar 12	Mar 11	Mar 10	Sep 09
# Analysts	-	-	-	16	10	9	9	13	9	9	15	9	9	16	8	10	16	18	19	8	8	13	14	16	11	11	16
Net Income	-	-	-	$33.31M	$-37.46M	$-110.11M	$-22.70M	$-28.59M	$-35.09M	$-37.27M	$-38.46M	$-33.29M	$-29.03M	$-29.23M	$-16.46M	$-14.45M	$-24.34M	$-30.05M	$-15.09M	$-20.54M	$-18.67M	$-16.64M	$-10.49M	$-8.89M	$-6.54M	$-6.66M	$-3.92M
Avg Forecast	$-44.23M	$-40.85M	$-65.92M	$-32.33M	$-41.38M	$10.51M	$-27.31M	$-33.48M	$-35.09M	$-40.05M	$-28.16M	$-33.96M	$-14.09M	$-23.18M	$-21.90M	$-26.85M	$-25.28M	$-30.05M	$-15.93M	$-15.28M	$-22.23M	$-13.31M	$-10.22M	$-9.14M	$-8.05M	$-6.44M	$-4.34M
High Forecast	$-31.10M	$-40.85M	$-65.92M	$-32.33M	$-33.10M	$10.51M	$-27.31M	$-33.48M	$-28.07M	$-40.05M	$-28.16M	$-33.96M	$-11.27M	$-23.18M	$-21.90M	$-26.85M	$-20.23M	$-24.04M	$-12.74M	$-12.23M	$-17.78M	$-10.65M	$-8.18M	$-7.31M	$-6.44M	$-5.15M	$-3.47M
Low Forecast	$-57.37M	$-40.85M	$-65.92M	$-32.33M	$-49.66M	$10.51M	$-27.31M	$-33.48M	$-42.11M	$-40.05M	$-28.16M	$-33.96M	$-16.91M	$-23.18M	$-21.90M	$-26.85M	$-30.34M	$-36.06M	$-19.11M	$-18.34M	$-26.67M	$-15.98M	$-12.26M	$-10.97M	$-9.66M	$-7.73M	$-5.21M
Surprise %	-	-	-	-1.03%	0.91%	-10.48%	0.83%	0.85%	1.00%	0.93%	1.37%	0.98%	2.06%	1.26%	0.75%	0.54%	0.96%	1.00%	0.95%	1.34%	0.84%	1.25%	1.03%	0.97%	0.81%	1.03%	0.90%

Omeros's average Quarter net income forecast for Jun 24 is $-65.92M, with a range of $-65.92M to $-65.92M. OMER's average Quarter net income forecast represents a -297.90% decrease compared to the company's last Quarter net income of $33.31M (Sep 22).

Omeros SG&A Forecast

	Dec 24	Sep 24	Jun 24	Sep 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13	Mar 12	Mar 11	Mar 10	Sep 09
# Analysts	-	-	-	16	10	9	9	13	9	9	15	9	9	16	8	10	16	18	19	8	8	13	14	16	11	11	16
SG&A	-	-	-	$12.20M	$10.96M	$-5.63M	$20.86M	$21.56M	$18.05M	$17.90M	$19.82M	$16.93M	$18.04M	$16.13M	$16.93M	$16.93M	$14.63M	$10.93M	$12.47M	$11.11M	$8.99M	$3.77M	$3.99M	$2.32M	$2.26M	$1.72M	$1.28M
Avg Forecast	-	-	-	$2.55M	$9.32M	$61.07M	$25.51M	$22.15M	$18.05M	$13.61M	$19.00M	$15.60M	$8.75M	$28.97M	$25.82M	$22.38M	$15.19M	$1.45M	$11.84M	$5.39M	$437.39K	$76.05K	$974.29K	$1.40M	$1.47M	$333.82K	$446.96K
High Forecast	-	-	-	$2.55M	$9.32M	$61.07M	$25.51M	$22.15M	$21.66M	$13.61M	$19.00M	$15.60M	$10.50M	$28.97M	$25.82M	$22.38M	$18.23M	$1.74M	$14.21M	$6.47M	$524.87K	$91.25K	$1.17M	$1.69M	$1.76M	$400.59K	$536.36K
Low Forecast	-	-	-	$2.55M	$9.32M	$61.07M	$25.51M	$22.15M	$14.44M	$13.61M	$19.00M	$15.60M	$7.00M	$28.97M	$25.82M	$22.38M	$12.16M	$1.16M	$9.47M	$4.31M	$349.91K	$60.84K	$779.43K	$1.12M	$1.18M	$267.06K	$357.57K
Surprise %	-	-	-	4.79%	1.18%	-0.09%	0.82%	0.97%	1.00%	1.32%	1.04%	1.09%	2.06%	0.56%	0.66%	0.76%	0.96%	7.55%	1.05%	2.06%	20.55%	49.54%	4.09%	1.65%	1.54%	5.16%	2.86%

Omeros's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to OMER last annual SG&A of $12.20M (Sep 22).

Omeros EPS Forecast

	Dec 24	Sep 24	Jun 24	Sep 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13	Mar 12	Mar 11	Mar 10	Sep 09
# Analysts	-	-	-	16	10	9	9	13	9	9	15	9	9	16	8	10	16	18	19	8	8	13	14	16	11	11	16
EPS	-	-	-	$0.53	$-0.60	$-1.76	$-0.36	$-0.46	$-0.57	$-0.60	$-0.66	$-0.61	$-0.53	$-0.58	$-0.33	$-0.29	$-0.50	$-0.62	$-0.34	$-0.54	$-0.51	$-0.54	$-0.40	$-0.40	$-0.30	$-0.31	$-1.34
Avg Forecast	$-0.76	$-0.70	$-1.14	$-0.56	$-0.66	$0.18	$-0.47	$-0.58	$-0.53	$-0.69	$-0.49	$-0.59	$-0.34	$-0.40	$-0.38	$-0.46	$-0.42	$-0.62	$-0.38	$-0.32	$-0.75	$-0.36	$-0.38	$-0.37	$-0.48	$-0.29	$-0.41
High Forecast	$-0.54	$-0.70	$-1.14	$-0.56	$-0.66	$0.18	$-0.47	$-0.58	$-0.53	$-0.69	$-0.49	$-0.59	$-0.34	$-0.40	$-0.38	$-0.46	$-0.42	$-0.50	$-0.30	$-0.26	$-0.60	$-0.29	$-0.30	$-0.30	$-0.38	$-0.23	$-0.33
Low Forecast	$-0.99	$-0.70	$-1.14	$-0.56	$-0.66	$0.18	$-0.47	$-0.58	$-0.53	$-0.69	$-0.49	$-0.59	$-0.34	$-0.40	$-0.38	$-0.46	$-0.42	$-0.74	$-0.46	$-0.38	$-0.90	$-0.43	$-0.46	$-0.44	$-0.58	$-0.35	$-0.49
Surprise %	-	-	-	-0.95%	0.91%	-9.71%	0.76%	0.80%	1.08%	0.87%	1.36%	1.04%	1.56%	1.45%	0.87%	0.63%	1.18%	1.00%	0.89%	1.69%	0.68%	1.50%	1.05%	1.08%	0.63%	1.07%	3.27%

According to 0 Wall Street analysts, Omeros's projected average Quarter EPS for Jun 24 is $-1.14, with a low estimate of $-1.14 and a high estimate of $-1.14. This represents a -314.65% decrease compared to OMER previous annual EPS of $0.53 (Sep 22).

Omeros Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PASG	Passage Bio	$0.48	$6.00	1150.00%	Buy
ENTA	Enanta Pharmaceuticals	$9.42	$65.67	597.13%	Buy
LYEL	Lyell Immunopharma	$1.11	$6.67	500.90%	Hold
GOSS	Gossamer Bio	$0.71	$3.75	428.17%	Buy
BMEA	Biomea Fusion	$6.42	$22.75	254.36%	Buy
ARQT	Arcutis Biotherapeutics	$10.09	$31.00	207.23%	Buy
FIXX	Q32 Bio	$0.93	$2.70	190.32%	Buy
DAWN	Day One Biopharmaceuticals	$13.52	$38.80	186.98%	Buy
STOK	Stoke Therapeutics	$11.61	$30.60	163.57%	Buy
ORIC	ORIC Pharmaceuticals	$8.89	$17.00	91.23%	Buy
DSGN	Design Therapeutics	$5.48	$9.67	76.46%	Buy
FOLD	Amicus Therapeutics	$9.52	$15.25	60.19%	Buy
CNTB	Connect Biopharma	$0.98	$1.50	53.06%	Buy
AKRO	Akero Therapeutics	$31.03	$46.00	48.24%	Buy
MIRM	Mirum Pharmaceuticals	$42.09	$57.25	36.02%	Buy
PTGX	Protagonist Therapeutics	$38.65	$50.00	29.37%	Buy
CRNX	Crinetics Pharmaceuticals	$55.17	$70.14	27.13%	Buy
RNA	Avidity Biosciences	$43.25	$54.50	26.01%	Buy
LGND	Ligand Pharmaceuticals	$111.80	$130.40	16.64%	Buy
RVMD	Revolution Medicines, Inc. Warrant	$56.47	$60.63	7.37%	Buy
VECT	VectivBio	$16.87	$18.00	6.70%	Buy
CERE	Cerevel Therapeutics	$44.96	$33.50	-25.49%	Buy
OMER	Omeros	$6.03	$2.00	-66.83%	Hold

OMER Forecast FAQ

Is Omeros a good buy?

No, according to 1 Wall Street analysts, Omeros (OMER) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of OMER's total ratings.

What is OMER's price target?

Omeros (OMER) average price target is $2 with a range of $2 to $2, implying a -66.83% from its last price of $6.03. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Omeros stock go up soon?

According to Wall Street analysts' prediction for OMER stock, the company can go down by -66.83% (from the last price of $6.03 to the average price target of $2), down by -66.83% based on the highest stock price target, and down by -66.83% based on the lowest stock price target.

Can Omeros stock reach $9?

OMER's average twelve months analyst stock price target of $2 does not support the claim that Omeros can reach $9 in the near future.

What are Omeros's analysts' financial forecasts?

Omeros's analysts financial forecasts for the fiscal year (Dec 2021) are as follows: average revenue is $139.67M (high $139.67M, low $139.67M), average EBITDA is $4.68M (high $10.64M, low $-1.283M), average net income is $-85.378M (high $-78.36M, low $-92.396M), average SG&A $126.78M (high $130.39M, low $123.17M), and average EPS is $-1.396 (high $-1.396, low $-1.396). OMER's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-151M (high $-138M, low $-164M), average SG&A $0 (high $0, low $0), and average EPS is $-2.606 (high $-2.379, low $-2.833).

Did the OMER's actual financial results beat the analysts' financial forecasts?

Based on Omeros's last annual report (Dec 2020), the company's revenue was $73.81M, which missed the average analysts forecast of $83.27M by -11.36%. Apple's EBITDA was $-110M, missing the average prediction of $4.26M by -2679.80%. The company's net income was $-138M, beating the average estimation of $-116M by 18.75%. Apple's SG&A was $72.7M, beating the average forecast of $56.97M by 27.60%. Lastly, the company's EPS was $-2.41, beating the average prediction of $-2.103 by 14.58%. In terms of the last quarterly report (Dec 2021), Omeros's revenue was $-79.889M, missing the average analysts' forecast of $66.92M by -219.38%. The company's EBITDA was $285.9M, beating the average prediction of $19.37M by 1376.29%. Omeros's net income was $-110M, missing the average estimation of $10.51M by -1148.03%. The company's SG&A was $-5.632M, missing the average forecast of $61.07M by -109.22%. Lastly, the company's EPS was $-1.76, missing the average prediction of $0.181 by -1070.66%